Editorial: Put Robots In The C-Suite!
This article was originally published in Scrip
Executive Summary
The pharma C-suite is beset by sickness. From exotic orphan conditions like Dys-shkreli-a (a dangerous propensity to drag the industry into disrepute that can be crippling for host companies) to pneumonia following intense scrutiny (Valeant's Pearson), the risks are many. Non-compete-itis saw off MannKind's new CEO before he'd even set foot in the corner office. Many companies watch millions of dollars bleeding uncontrollably out through their C-suites with no effective clotting agent available to staunch the flow.